Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVERT-PREDIABETES
2025-522970-35-00Phase 4Authorised
- Sponsor
- Central Denmark Region
- Start
- Nov 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dapagliflozin and semaglutide in prediabetes, type 2 diabetes mellitus (T2DM), coronary arteriosclerosis and 4 more (2 arms), sponsored by Central Denmark Region. Primary endpoints: Composite microvascular and MASLD complications by glycemic status and Incidence of normoglycemia (HbA1c <39 mmol/mol) at 1 year. Planned start Nov 2025; status: authorised.
02
Drugs
dapagliflozinsemaglutide
03
Conditions
prediabetestype 2 diabetes mellitus (T2DM)coronary arteriosclerosismetabolic dysfunction-associated steatotic liver disease (MASLD)diabetic retinopathy (DR)
Beyond the preview
Go deeper on 2025-522970-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522970-35-00.